Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.

Source: Guanlan Pharmaceutical

On April 20, Microchip released an announcement that the phase 2 trial of chidamide combined with envolimab in the treatment of non-small cell lung cancer (NSCLC) patients who have been treated with PD-1 inhibitors has been received by the Chinese government.

Chidamide: The combined anti-PD-L1 antibody phase 2 clinical trial has been accepted.

According to the announcement, the NMPA accepted this time is an open, multi-center phase 2 clinical study of chidamide combined with envolimab in the treatment of NSCLC patients who have been treated with PD-1 inhibitors.

Sioroni: successively approved for clinical trials in China and the United States

Chiauranib (CS2164) is a multi-target multi-pathway selective kinase inhibitor that can exert comprehensive anti-tumor effects through three active mechanisms, including: ①Inhibition of tumors by inhibiting the cell cycle regulatory kinase Aurora B Cell cycle progression; ②Inhibit tumor neovascularization by inhibiting angiogenesis-related VEGFR and PDGFR; ③Inhibit tumor local immunosuppressive cell growth by inhibiting CSF1R related to immune cell proliferation and activation.

On April 16, Microchip issued an announcement stating that a randomized, double-blind, controlled, multi-center phase 3 clinical trial of Cioroni combined with paclitaxel weekly therapy for platinum-refractory or platinum-resistant relapsed ovarian cancer (CHIPRO ) Has also been approved in China.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

[1] Voluntary disclosure of announcement on acceptance of clinical trial applications.

▽ attention [drug Mingkang Germany ] micro-channel public number